{"groups":[{"description":"Participants were administered pazopanib 800 milligrams (mg) (2 x 400 mg tablets) orally once daily (OD) continuously. Pazopanib was to be taken at least one hour before or at least two hours after a meal. Participants received study treatment until disease progression, death, unacceptable toxicity, or withdrawal of consent for any other reasons.","id":"FG000","title":"Pazopanib 800 mg"},{"description":"Participants were administered sunitinib 50 mg orally once daily in 6-week cycles (4 weeks of treatment, followed by 2 weeks without treatment). Participants received study treatment until disease progression, death, unacceptable toxicity, or withdrawal of consent for any other reasons.","id":"FG001","title":"Sunitinib 50 mg"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"2"}],"type":"Protocol Violation"},{"reasons":[{"groupId":"FG000","numSubjects":"8"},{"groupId":"FG001","numSubjects":"7"}],"type":"Transitioned to another mechanism of continuing pazopanib or sunitinib therapy after 30SEP2013"},{"reasons":[{"groupId":"FG000","numSubjects":"20"},{"groupId":"FG001","numSubjects":"15"}],"type":"Lost to Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"14"},{"groupId":"FG001","numSubjects":"12"}],"type":"Physician Decision"},{"reasons":[{"groupId":"FG000","numSubjects":"29"},{"groupId":"FG001","numSubjects":"36"}],"type":"Withdrawal by Subject"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"557"},{"groupId":"FG001","numSubjects":"553"}],"comment":"All randomized subjects from Study A2301 and Study A2201 were included in the Intent-to-Treat (ITT) Population","type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"554"},{"groupId":"FG001","numSubjects":"548"}],"comment":"All randomized subjects from Study A2301 and Study A2201 who received at least one dose of study treatment were included in the Safety Population","type":"Safety Population"},{"achievements":[{"groupId":"FG000","numSubjects":"485"},{"groupId":"FG001","numSubjects":"481"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"72"},{"groupId":"FG001","numSubjects":"72"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"Participants were stratified based on Karnofsky Performance Scale scores (70 or 80; 90 or 100), Baseline levels of lactate dehydrogenase (\\>1.5 versus \\<=1.5 times the upper limit of normal \\[ULN\\]), and previous nephrectomy (yes versus no) and were randomized in a 1:1 ratio to receive either pazopanib or sunitinib."}